RISA Labs, an AI-driven healthtech startup focused on streamlining cancer care operations, has raised $11.1 million (about ₹91 crore) in a new funding round to scale its technology across oncology networks and deepen its presence in hospital systems and enterprise providers.
Investors and significance of the round
The round was co‑led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures and Ventureforgood. Early backer Binny Bansal also participated, continuing his support from the seed stage. The mix of strategic healthcare investors signals growing confidence in AI solutions that tackle operational inefficiencies in clinical care delivery.
Building an AI operating system for oncology workflows
Founded by Kshitij Jaggi and Kumar Shivang, RISA Labs is developing an “AI operating system” designed to manage complex administrative and clinical processes in oncology. The platform uses AI agents to automate repetitive tasks, integrate data across disparate systems and streamline workflows that are traditionally manual and time‑consuming.
Oncology practices frequently contend with fragmented IT environments, prolonged approval cycles, insurance authorisations, benefits verification and care coordination bottlenecks. These operational frictions can delay treatment and impair patient experience; RISA’s technology aims to reduce such delays by automating prior authorisations, benefits checks and related tasks so clinicians and care teams can focus more on clinical care.
Use of funds: product development and deployments
RISA plans to allocate the new capital to accelerate product development, expand deployments across US hospitals and cancer care networks, and strengthen technical integrations. A significant portion will be invested in connecting the platform with electronic health records (EHRs), payer systems and internal clinical tools to enable seamless data flow and automation.
The company is also prioritising customer growth by onboarding more oncology providers and enterprise healthcare organisations to demonstrate measurable gains in operational efficiency, reduced turnaround times and improved care delivery metrics.
Early traction and real‑world impact
RISA Labs reports encouraging early traction: its AI‑driven workflows have reduced manual workload for administrative staff and accelerated approvals in many instances. By enabling AI agents to act across multiple systems with minimal human intervention, the platform functions as a digital extension of care teams—navigating complex processes at scale and with consistent outcomes.
Investor confidence and outlook
The participation of global, healthcare‑focused investors underscores a broader belief that AI can transform healthcare operations. Continued backing from Binny Bansal adds strategic credibility from the Indian entrepreneurial ecosystem, which has emphasised scalable, tech‑first approaches to systemic problems.
As RISA Labs advances into its next growth phase, the healthtech and AI communities will watch for measurable improvements in oncology operations. If successful, the company could materially reduce administrative friction in cancer care, improving speed, efficiency and patient experience through intelligent automation.
